《COMMIT CCS-2研究PPT课件》由会员分享，可在线阅读，更多相关《COMMIT CCS-2研究PPT课件（12页珍藏版）》请在金锄头文库上搜索。
1、Perspective on COMMIT/CCS-2 Trial of Metoprolol in STEMI,Christopher Cannon, M.D. Brigham and Womens Hospital Boston, MA,First impression,Wow !? I had predicted dramatic benefit with multiple 0s in the P value,Older B-blocker trials (up to 1986),27,000 patients from 28 trials Meta-analysis: B-blocke
2、r (3.7%) Control (4.3%) 16% relative risk reduction 95% CI: 1-30% P=0.02 On re-looking: Lower risk patients studied Wide confidence intervals on mortality benefit,Evolution of use of B-Blockers in AMI,Benefits seen in meta-analysis of RCTs: reduced mortality, re-MI, VF, rec. ischemia Initially contr
3、aindicated if CHF Then, trials in outpatients with LV dysfunction, (with slow up-titration of dose over 3-6 mos) B-blockers shown to reduce mortality The overlap: in AMI, CHF no longer seen as a contraindication to use of B blockers,Looking at the data in COMMIT/CCS-2,Benefit Reduction in re-MI Redu
4、ction in VF Risk Increased development of cardiogenic shock Biologically plausible a negative inotropic agent Increased risk of shock in first 24-48 hours Subgroup analysis: Shock developed in Patients with Killip III, tachycardia, or hypotension,Class I: Oral -blocker therapy should be administered
5、 promptly to those patients without a contraindication, irrespective of concomitant fibrinolytic therapy or performance of primary PCI. (Level of evidence: A) Class IIa: It is reasonable to administer iv -blocker promptly to STEMI patients without contraindications, especially if a tachyarrhythmia o
6、r hypertension is present. (Level of evidence: B),Current ACC/AHA guideline on the use of early -blocker in acute MI (ACC/AHA Task Force Report. J Am Coll Cardiol 2004;44:671-719,the use of iv -blockade in the acute phase of infarction in many countries is extremely low. There is a good case for the
7、 greater use of an iv -blocker when there is tachycardia (in the absence of heart failure), relative hypertension, or pain unresponsive to opioids. It may be prudent to test the patients response to this form of therapy by first using a short-acting preparation. In most patients, however, oral -bloc
8、kade will suffice.,Current ESC Guideline for the use of early -blocker in acute MI (ESC Task Force Report. Euro Heart J 2003;24:28-66,Conclusions: B-Blockade in Acute MI,One size does not fit all Avoid IV B-blocker for patients with evidence of compromised LV Function Start oral B blocker after 1-2
9、days, when stable with lower doses, and titrate upward Low-medium risk patients benefit from early IV - oral beta-blockade For all medications: Need to balance benefit and risk, for each patient,Lessons Learned from 2x2 Clinical Trials,In 2x2 trial, if one is + and the other -, it provides a negativ
10、e control that reinforces the positive intervention ISIS-4/ AMI ACE inhibitor +benefit GISSI-3 Nitrates no benefit HOPE Vasc. ACE inhibitor +benefit GISSI-Prev. Dis Vit E no benefit PROVE IT- ACS High-dose statin +benefit TIMI 22 Antibiotic no benefit COMMIT/ AMI Clopidogrel +benefit CCS-2 Metoproto
11、l +/-benefit,COMMIT/CCS-2: Major contribution,10 million AMI/year worldwide, 3 million STEMI For metoprolol, We learn appropriate use for well-established class New data will avoid excess risk, but allow benefit in appropriate patients For clopidogrel, New addition for treatment for STEMI Improved p
12、atency, mortality and morbidity Could prevent 20,000 30,000 deaths, MIs or strokes per year worldwide,-blocker use Outcome Immediate Deferred 2P (n=720) (n=714) values Death at day 7 17 17 0.98 Death or reinfarction 34 50 0.07 Reinfarction 75 87 0.02 Recurrent chest pain 134 170 0.02,TIMI-IIB: Effects of early -blocker following lytic therapy in acute MI,Circulation 1991:83:422-37,
